Québec City, Canada, June 14, 2010 – Aeterna Zentaris Inc. (Nasdaq: AEZS; TSX: AEZ), (the “Company”) a late-stage drug development company specialized in oncology and endocrine therapy, today announced that a poster on its oral synthetic growth hormone secretagogue/ghrelin receptor agonist, AEZS-130, will be presented at the upcoming 92nd Annual Endocrine Society (ENDO) Meeting and Expo, which will be held June 19 through 22, 2010 at the San Diego Convention Center in San Diego, California. AEZS-130 (SolorelTM) is currently in a Phase 3 trial as a diagnostic test for growth hormone deficiency in adults.
Abstract #851112: “Pharmacological and Toxicological Evaluation of AEZS-130, a Novel, Oral Synthetic Growth Hormone Secretagogue//Ghrelin Receptor Agonist for the Diagnosis of Growth Hormone Deficiency”, Babette Aicher, Peter Schmidt, Elena Bresciani, Vittorio Locatelli, Daniel Perrissoud, Michael Teifel
Presenter: Dr. Babette Aicher, Associate Director - Screening & Profiling, Preclinical Development, Aeterna Zentaris Date and Time: Sunday, June 20, 2010, 1:30 pm - 3:30 pm (local time) Poster Board #: P2-340 Location: Halls D-G, San Diego Convention Center
A copy of this abstract is currently available on the ENDO website at www.endo-society.org.
About Aeterna Zentaris Inc.
Aeterna Zentaris Inc. is a late-stage drug development company specialized in oncology and endocrine therapy. News releases and additional information are available at www.aezsinc.com.
Investor Relations Ginette Vallières Investor Relations Coordinator (418) 652-8525 ext. 265 gvallieres@aezsinc.com
Media Relations Paul Burroughs Director of Communications (418) 652-8525 ext. 406 pburroughs@aezsinc.com
